Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Duplicate Therapy Prior Auth Update | O…
    Ask Trek AI about this page
    CurrentQualChoicePolicy AR.QC.CP.PMN.04

    Duplicate Therapy

    Customize your policy alerts

    Sign up for QualChoice Policy AR.QC.CP.PMN.04 alerts

    Get alerted when Policy AR.QC.CP.PMN.04 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs pharmacy-level duplicate therapy edits that limit members from receiving multiple medications within the same or similar drug classes and defines prior authorization and documentation requirements for overrides; it applies to QualChoice Commercial membership unless state Medicaid overrides apply as noted.

    Policy Summary
    PayerQualChoice
    PolicyDuplicate Therapy
    Policy CodePolicy AR.QC.CP.PMN.04
    Change TypeRevised approval duration
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with clinical documentation to support medical necessity for duplicate therapy; pharmacist will review and may approve when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    Approval duration for therapy changes and dose titrations updated from 12 months to 30 days.

    1/moGLP-1 restriction
    1/moTNFα restriction
    1/moCGRP restriction
    30 daysApproval duration
    Policy Summary
    PayerQualChoice
    PolicyDuplicate Therapy
    Policy CodePolicy AR.QC.CP.PMN.04
    Change TypeRevised approval duration
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with clinical documentation to support medical necessity for duplicate therapy; pharmacist will review and may approve when criteria are met.
    SourceLink
    On This Page
    Coverage Criteria — Duplicate TherapyProvider Actions, Prior Authorization, and DocumentationBackground and RationaleDefinitionsInitial Duplicate Therapy ConstraintsStep Therapy / Pharmacist Review

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria — Duplicate Therapy

    Situations where duplicate therapy may be approved

    Pharmacist may approve when at least one of the following applies:

    Approval examples: Provider is changing therapy (discontinuing duplicate agent)

    Approval duration: 30 days for therapy changes and dose titration; approvals based on medical literature may be granted for 12 months when supported as standard of care.

    Approval examples: Provider is requesting multiple strengths of the same drug for dose titration

    Approval duration: 30 days for therapy changes and dose titration; approvals based on medical literature may be granted for 12 months when supported as standard of care.

    Approval examples: Requested therapy is supported by medical literature as standard of care

    Approval duration: 12 months when therapy is supported by medical literature and considered standard of care.

    Not medically necessary — duplicate therapy without justification

    Not covered when ALL of the following are true:

    Standard denial: Request exceeds class-specific restriction and provider has not submitted documentation establishing medical necessity or standard-of-care justification.

    Such cases should be denied based on the restrictions identified by drug class.

    For members covered by Medicaid, state Medicaid coverage provisions take precedence when they conflict with the coverage provisions in this clinical policy. Providers should consult the applicable state Medicaid manual for any differing coverage rules before seeking an override or prior authorization under this policy.

    Requests that exceed the listed drug-class restrictions are considered not medically necessary and should be denied when the provider has not submitted documentation establishing medical necessity or a standard-of-care justification. If clinical justification is not provided, the case should be denied based on the restrictions identified by drug class.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required for duplicate therapy

    Prior authorization is required for any claim that triggers a duplicate therapy restriction; overrides are not available at point-of-sale and the request must be submitted for pharmacist review.

    Step Therapy

    Pharmacist review and potential approval

    A pharmacist will review prior authorization requests that exceed the class-specific duplicate therapy restrictions and may approve the request if it is medically necessary and within the standard of care.

    • Pharmacist may approve when provider is changing therapy (discontinuing duplicate agent) — approval duration: 30 days
    • Pharmacist may approve for multiple strengths for dose titration — approval duration: 30 days
    • Pharmacist may approve when requested therapy is supported by medical literature as standard of care — approval duration: 12 months
    Documentation Required

    Clinical supporting documentation required

    Providers must submit supporting clinical documentation (for example, office chart notes, laboratory results, or other clinical information) with the prior authorization to establish medical necessity for duplicate therapy.

    • Include office chart notes, lab results, or other relevant clinical information demonstrating medical necessity or standard-of-care justification.
    Denial Risk

    Denial trigger when medical necessity not established

    If the provider does not establish medical necessity or a standard-of-care justification, the request must be denied based on the drug-class restrictions.

    Background and Rationale

    Duplicate therapy edits are applied at the pharmacy level to prevent members from receiving excessive or overlapping medication regimens within the same or similar drug classes. These edits require pharmacist review and a prior authorization process to permit clinically justified exceptions such as therapy changes (including discontinuation of a duplicate agent) or dose titration. When approved for these reasons, approval durations for therapy changes and dose titrations default to 30 days, while therapies supported by medical literature and considered standard of care may be approved for longer durations.

    Definitions

    Duplicate therapy edit — definition and key points
    DefinitionCases where a member is prescribed more than the allowed number of drugs within the same or similar drug class (e.g., multiple GLP-1 receptor agonists).
    Primary purposeTo prevent members from receiving excessive medication regimens within the same or similar drug classes through pharmacy-level duplicate therapy edits.
    When prior authorization is requiredPrior authorization is required for review when claims trigger duplicate therapy restrictions and overrides are not available at point-of-sale; a pharmacist must review requests that exceed class-specific restrictions.
    Examples that may justify duplicate therapy approvalProvider is changing therapy (discontinuing duplicate agent); provider is requesting multiple strengths of the same drug for dose titration; requested therapy is supported by medical literature as standard of care.
    Approval durations30 days for therapy changes and dose titration; 12 months when therapy is supported by medical literature and considered standard of care.

    Initial Duplicate Therapy Constraints

    Initial duplicate therapy constraints

    Class-specific restriction summary

    Class restrictions: Certain drug classes are restricted to one drug per month (e.g., Glucagon Like Peptide-1 (GLP-1) receptor agonists; Tumor Necrosis Factor (TNF) alpha inhibitors; Calcitonin Gene-Related Peptide (CGRP) inhibitors).1 drug per month

    Pharmacist review and prior authorization required for exceptions.

    Step Therapy / Pharmacist Review

    StepRequirement
    1Pharmacist shall review prior authorization requests that exceed class-specific restrictions; pharmacist may approve the request if medically necessary and within standard of care. Examples include: provider changing therapy (discontinuing duplicate agent) — approval duration: 30 days; provider requesting multiple strengths of the same drug for dose titration — approval duration: 30 days; therapy supported by medical literature as standard of care — approval duration: 12 months. If medical necessity is not established the case should be denied based on the restrictions identified by drug class.